Hemopatch® is effective and safe to use: real-world data from a prospective European registry study

Carlo Lombardo, Santiago Lopez-Ben, Ugo Boggi, Piotr Gutowski, Tomas Hrbac, Lukas Krska, Javier Marquez-Rivas, Domenico Russello, Elisa York, Mario Zacharias, Carlo Lombardo, Santiago Lopez-Ben, Ugo Boggi, Piotr Gutowski, Tomas Hrbac, Lukas Krska, Javier Marquez-Rivas, Domenico Russello, Elisa York, Mario Zacharias

Abstract

Surgical procedures are often impeded by bleeding and/or leakage of body fluids. These complications cannot always be resolved by conventional surgical techniques. Hemopatch® is a hemostatic patch that also functions as a sealant. Here we document the effectiveness and safety of Hemopatch® for routine procedures of multiple surgical disciplines. To this end, we performed a prospective, multicenter, single-arm, observational registry study. Patients were eligible if they had received Hemopatch® during an open or minimally invasive procedure in one of these specialties: hepatobiliary, cardiovascular, urological, neurological/spinal, general, or lung surgery. Patients were excluded if they had a known hypersensitivity to bovine proteins or brilliant blue, intraoperative pulsatile or severe bleeding and/or infection at the target application site (TAS). The primary endpoint for intraoperative effectiveness was hemostasis assessed as the percentage of patients achieving hemostasis within 2 min and the percentage of patients achieving hemostasis without re-bleeding at the time of surgical closure. The registry enrolled 621 patients at 23 study sites in six European countries. Six hundred twenty patients had completed follow-up information. Hemostasis within 2 min was achieved at 463 (74.5%) of all 621 TASs. Hemostasis without re-bleeding was observed at 620 (99.8%) TASs. Adverse events were reported in 64 patients (10.3%). This Hemopatch® registry shows that Hemopatch® efficiently establishes hemostasis and sealing in a variety of surgical specialties, including minimally invasive procedures. Furthermore, we provide evidence for the safety of Hemopatch® across all the specialties included in the registry. This study is registered at clinicaltrials.gov: NCT03392662.

Keywords: Hemopatch®; Hemostasis; Minimally invasive procedures; Sealing.

Conflict of interest statement

Santiago Lopez-Ben, Lukas Krska, Javier Marquez-Rivas, Domenico Russello, Elisa York, and Mario Zacharias received honoraria from Baxter as advisors for interpreting the raw data and consulting in stratification and interpretation of data in post hoc analyses.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Patient disposition. *One patient was included in both cohorts since he had two target application sites: one at the mesocolon (general cohort) and one at the liver (hepatobiliary cohort). AE adverse event; FAS full analysis set; FU follow-up; SAS safety analysis set

References

    1. Zegers M, de Bruijne MC, de Keizer B, Merten H, Groenewegen PP, van der Wal G, Wagner C. The incidence, root-causes, and outcomes of adverse events in surgical units: implication for potential prevention strategies. Patient Saf Surg. 2011;5:13. doi: 10.1186/1754-9493-5-13.
    1. Bracey A, Shander A, Aronson S, Boucher BA, Calcaterra D, Chu MWA, Culbertson R, Jabr K, Kehlet H, Lattouf O, Malaisrie SC, Mazer CD, Oberhoffer MM, Ozawa S, Price T, Rosengart T, Spiess BD, Turchetti G. The use of topical hemostatic agents in cardiothoracic surgery. Ann Thorac Surg. 2017;104(1):353–360. doi: 10.1016/j.athoracsur.2017.01.096.
    1. Lewis KM, Ikeme S, Olubunmi T, Kuntze CE. Clinical effectiveness and versatility of a sealing hemostatic patch (HEMOPATCH) in multiple surgical specialties. Expert Rev Med Dev. 2018;15(5):367–376. doi: 10.1080/17434440.2018.1464909.
    1. Light RU, Prentice HR. Surgical investigation of a new absorbable sponge derived from gelatin for use in hemostasis. J Neurosurg. 1945;2(5):435–455. doi: 10.3171/jns.1945.2.5.0435.
    1. Lewis KM, Kuntze CE, Gulle H. Control of bleeding in surgical procedures: critical appraisal of HEMOPATCH (Sealing Hemostat) Med Devices (Auckl) 2015;22(9):1–10. doi: 10.2147/MDER.S90591.
    1. Fingerhut A, Uranues S, Ettorre GM, Felli E, Colasanti M, Scerrino G, Melfa GI, Raspanti C, Gulotta G, Meyer A, Oberhoffer M, Schmoeckel M, Weltert LP, Vignolini G, Salvi M, Masieri L, Vittori G, Siena G, Minervini A, Serni S, Carini M. European initial hands-on experience with HEMOPATCH, a novel sealing hemostatic patch: application in general, gastrointestinal, biliopancreatic, cardiac, and urologic surgery. Surg Technol Int. 2014;25:29–35.
    1. Imkamp F, Tolkach Y, Wolters M, Jutzi S, Kramer M, Herrmann T. Initial experiences with the Hemopatch(R) as a hemostatic agent in zero-ischemia partial nephrectomy. World J Urol. 2015;33(10):1527–1534. doi: 10.1007/s00345-014-1404-4.
    1. Ruggiero R, Docimo L, Tolone S, De Palma M, Musella M, Pezzolla A, Gubitosi A, Parmeggiani D, Pirozzi R, Gili S, Parisi S, D'Alessandro A, Docimo G. Effectiveness of an advanced hemostatic pad combined with harmonic scalpel in thyroid surgery. A prospective study. Int J Surg (Lond, Engl) 2016;28(Suppl 1):S17–21. doi: 10.1016/j.ijsu.2015.12.044.
    1. Prasad M, Mukerji N. Case report of a novel technique for repair of the vertebral artery during cranial surgery. Neurol Therapy. 2019;8(2):505–509. doi: 10.1007/s40120-019-0142-3.
    1. Schebesch KM, Brawanski A. Clinical experience with Hemopatch(R) as a dural sealant in cranial neurosurgery. Cureus. 2019;11(2):e4013. doi: 10.7759/cureus.4013.
    1. Hupe MC, Büttner M, Tabrizi PF, Merseburger AS, Kuczyk MA, Imkamp F. Hemopatch(®) as a hemostatic agent is safe in partial nephrectomy: a large, single-surgeon retrospective evaluation. Adv Ther. 2020 doi: 10.1007/s12325-020-01584-8.
    1. Weltert L, D'Aleo S, Chirichilli I, Falco M, Turani F, Bellisario A, De Paulis R. Prospective Randomized Clinical Trial of HEMOPATCH Topical Sealant in Cardiac Surgery. Surg Technol Int. 2016 Oct;XXIX:sti29:756.
    1. Di Cesare T, Scarinci A, Cavaniglia D, Brun S, Cilurso F, Cosenza G, Grillo M, Costigliola L, Di Gioia G, Perfetto D, Buonanno GM, Travaglino A, Liverani A. Efficacy of Hemopatch® in reducing postoperative bleeding after laparoscopic cholecystectomy: Prospective and multicenter study. Integr Clin Med. 2018;2(4):1–3. doi: 10.15761/ICM.1000133.
    1. Nowak S, Schroeder HWS, Fleck S. Hemopatch((R)) as a new dural sealant: a clinical observation. Clin Neurol Neurosurg. 2019;176:133–137. doi: 10.1016/j.clineuro.2018.12.009.
    1. Pisapia A, Crolla E, Saracco M, Saglioccolo A, Dolce P, Molino C. The effectiveness of Hemopatch™ in preventing postoperative distal pancreatectomy fistulas. Expert Rev Med Dev. 2019;16(3):253–256. doi: 10.1080/17434440.2019.1582328.
    1. Ulrich F, Ettorre GM, Weltert L, Oberhoffer M, Kreuwel H, De Santis R, Kuntze E. Intra-operative use of Hemopatch(R): interim results of a nationwide European survey of surgeons. Surg Technol Int. 2016;28:19–28.
    1. Olthof PB, Rassam F, van Gulik TM. The use of a NHS-PEG coated, collagen-based sealant in a patient undergoing Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS) Int J Surg Case Rep. 2018;47:7–10. doi: 10.1016/j.ijscr.2018.03.038.
    1. Uranues S, Fingerhut A, Belyaev O, Zerbi A, Boggi U, Hoffmann MW, Reim D, Esposito A, Primavesi F, Kornprat P, Coppola R, Fragulidis GP, Serradilla-Martin M, Alimoglu O, Peri A, Diaconescu B. Clinical impact of stump closure reinforced with hemopatch on the prevention of clinically relevant pancreatic fistula after distal pancreatectomy: a multicenter randomized trial. Ann Surg Open. 2021;2(1):e033. doi: 10.1097/as9.0000000000000033.
    1. Ho Y-F, Hu F-C, Lee P-I. The advantages and challenges of using real-world data for patient care. Clin Transl Sci. 2020;13(1):4–7. doi: 10.1111/cts.12683.
    1. Lewis KM, Li Q, Jones DS, Corrales JD, Du H, Spiess PE, Lo Menzo E, DeAnda A., Jr Development and validation of an intraoperative bleeding severity scale for use in clinical studies of hemostatic agents. Surgery. 2017;161(3):771–781. doi: 10.1016/j.surg.2016.09.022.
    1. HEMOPATCH® . Sealing Hemostat-instructions for use BE-30–03–130. Zurich: Baxter Healthcare SA; 2018.
    1. Genyk Y, Kato T, Pomposelli JJ, Wright JK, Jr, Sher LS, Tetens V, Chapman WC. Fibrin sealant patch (TachoSil) vs oxidized regenerated cellulose patch (Surgicel Original) for the secondary treatment of local bleeding in patients undergoing hepatic resection: a randomized controlled trial. J Am Coll Surg. 2016;222(3):261–268. doi: 10.1016/j.jamcollsurg.2015.12.007.
    1. Maisano F, Kjaergård HK, Bauernschmitt R, Pavie A, Rábago G, Laskar M, Marstein JP, Falk V. TachoSil surgical patch versus conventional haemostatic fleece material for control of bleeding in cardiovascular surgery: a randomised controlled trial. Eur J Cardiothorac Surg. 2009;36(4):708–714. doi: 10.1016/j.ejcts.2009.04.057.
    1. Siemer S, Lahme S, Altziebler S, Machtens S, Strohmaier W, Wechsel HW, Goebell P, Schmeller N, Oberneder R, Stolzenburg JU, Becker H, Lüftenegger W, Tetens V, Van Poppel H. Efficacy and safety of TachoSil as haemostatic treatment versus standard suturing in kidney tumour resection: a randomised prospective study. Eur Urol. 2007;52(4):1156–1163. doi: 10.1016/j.eururo.2007.04.027.
    1. Ramirez MG, Serradilla M, Ramirez MA. Cost-benefit analysis: hemopatch® vs standard of care in the incidence of postoperative pancreatic fistula in a observational study. Am J Biomed Sci Res. 2019;1(1):11–19. doi: 10.34297/AJBSR.2019.01.000504.
    1. Anderson PA, Savage JW, Vaccaro AR, Radcliff K, Arnold PM, Lawrence BD, Shamji MF. Prevention of surgical site infection in spine surgery. Neurosurgery. 2017;80(3s):S114–S123. doi: 10.1093/neuros/nyw066.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit